Cytosine arabinoside for induction, salvage, and consolidation therapy of adult acute lymphoblastic leukemia.
During A-ALL induction treatment, HD-ara-C (2.5 g/m2 IV, day 1), does not produce any beneficial effect, whereas the hematologic toxicity is increased. A 3-month consolidation phase comprising intermittent MTX, ara-C and 6-TG is not significantly affecting either DFI or survival in A-ALL. The association of HD-ara-C and m-AMSA appears to be a promising salvage therapy for the 20% A-ALL refractory to first induction therapy. The quality of autologous bone marrow graft, harvested after HD-ara-C, seems to be impaired as suggested by a delayed recovery of PMN and platelets. HD-ara-C (3 g/m2 X N) given the days before cyclophosphamide and TBI as conditioning treatment for BMT does not seem to induce prohibitory additional toxicity. Whether HD-ara-C was given four to six times or eight to 12 times gave no significant difference in early toxicity.
Stryckmans
P
P
De Witte
T
T
Bitar
N
N
Marie
J P
JP
Suciu
S
S
Solbu
G
G
Debusscher
L
L
Bury
J
J
Peetermans
M
M
Andrien
J M
JM
D000328:Adult; D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016026:Bone Marrow Transplantation; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy* / Q000628:therapy; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D000677:Amsacrine; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D013866:Thioguanine; D002330:Carmustine; D011241:Prednisone; D008727:Methotrexate; D003630:Daunorubicin